Media headlines about NewLink Genetics (NASDAQ:NLNK) have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. NewLink Genetics earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.8915068725934 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news headlines that may have impacted Accern’s scoring:
- Zacks: Analysts Expect NewLink Genetics Co. (NLNK) Will Post Earnings of -$0.58 Per Share (americanbankingnews.com)
- Technical Indicators: NewLink Genetics Corporation (NLNK) (stockquote.review)
- Overbought Condition Now? NewLink Genetics Corporation (NLNK) (nysestocks.review)
- Mind-boggling Three Stocks: VAALCO Energy, Inc. (NYSE:EGY), NewLink Genetics Corporation (NASDAQ:NLNK … (thestreetpoint.com)
- NewLink Genetics: Explicating The Changing Fundamentals Of A Potential Comeback (seekingalpha.com)
Several research firms have recently commented on NLNK. SunTrust Banks cut NewLink Genetics from a “buy” rating to a “hold” rating and lowered their target price for the company from $19.00 to $5.00 in a research note on Friday, April 6th. Bank of America lowered their target price on NewLink Genetics from $22.00 to $18.00 and set a “buy” rating for the company in a research note on Friday, March 2nd. Cantor Fitzgerald set a $26.00 price objective on NewLink Genetics and gave the stock a “buy” rating in a research note on Friday, April 6th. ValuEngine cut NewLink Genetics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, May 8th. Finally, Zacks Investment Research raised NewLink Genetics from a “hold” rating to a “buy” rating and set a $5.50 price objective for the company in a research note on Saturday, May 5th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $10.50.
Shares of NewLink Genetics traded down $0.02, reaching $5.07, during trading on Friday, Marketbeat.com reports. The stock had a trading volume of 775,213 shares, compared to its average volume of 748,172. The firm has a market cap of $188.43 million, a price-to-earnings ratio of -2.20 and a beta of 1.25. NewLink Genetics has a 52 week low of $3.75 and a 52 week high of $19.30.
NewLink Genetics (NASDAQ:NLNK) last issued its quarterly earnings results on Thursday, May 3rd. The biotechnology company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.06. The company had revenue of $9.90 million for the quarter, compared to analyst estimates of $5.78 million. NewLink Genetics had a negative return on equity of 55.64% and a negative net margin of 193.44%. analysts expect that NewLink Genetics will post -2.17 earnings per share for the current fiscal year.
About NewLink Genetics
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing NLG2103, a combination of indoximod and standard of care checkpoint inhibitors, which is in Phase II clinical trial for treating patients with advanced melanoma; and Indigo301, a combination of indoximod with a checkpoint inhibitor that is in Phase III clinical trial for treating patients with advanced unresectable or metastatic melanoma, as well as combination of indoximod with other cancer therapeutics for patients with melanoma, pancreatic cancer, pediatric brain tumors, and acute myeloid leukemia.
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.